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Abstract 1 
Background 2 
Medication reviews have been introduced as healthcare interventions to decrease 3 
inappropriate polypharmacy in older patients, but implementation in practice is challenging.  4 
Objective 5 
This case study aimed to explore the events, actions and other factors that were involved in 6 
the implementation and sustainability of medication reviews in older patients by clinical 7 
pharmacists in Region Uppsala, Sweden. 8 
Methods 9 
A case study design informed by change management principles (Kotter) and normalization 10 
process theory, consisting of a review of published and grey literature, key informant 11 
interviews and focus group triangulation. Findings from additional literature review and 12 
interviews were integrated into a final thematic analysis. Ten healthcare professionals, 13 
managers and policy makers participated as key informants. The study included data up to 14 
2015. 15 
Results 16 
Factors were identified across all Kotter’s principles and normalization process theory 17 
domains, ranging from the first evidence on inappropriate polypharmacy in the 1980s until the 18 
creation of permanent clinical pharmacist positions in recent years. Examples of facilitating 19 
factors were a national focus on quality of care for the elderly, multiprofessional teamwork, 20 
key individuals of different professions, education, financial support and local evidence. 21 
Barriers included an unclear allocation of tasks and responsibilities, a lack of time and 22 
continuity, and a lack of a national plan for implementation, monitoring and evaluation. 23 
Conclusions 24 
Multiple factors across the full range of change management and implementation principles 25 
were involved in the implementation and sustainability. A systems approach, including these 26 
factors, should be considered in similar future initiatives, both in Sweden and settings in other 27 
countries. 28 
 29 
Keywords 30 
Implementation research; Change management; Multiprofessional teams; Medication 31 
management; Clinical pharmacy; Case study 32 
 33 
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Introduction 1 
Worldwide, people live longer and the population is ageing. As a consequence, the 2 
prevalence of chronic diseases and the use of medications are rising, which puts 3 
pressure on the sustainability of healthcare systems.1 Polypharmacy, the prescribing of 4 
multiple medications, is often necessary to treat the individual’s medical conditions.2 5 
However, inappropriate polypharmacy, the prescribing of multiple medicines which are 6 
either inappropriate or no longer indicated,3 is common among older patients. The 7 
prevalence of inappropriate prescribing in older patients in Sweden and other developed 8 
countries ranges from 20 – 50 %.4,5 It is associated with adverse drug events, leading to 9 
unnecessary hospital admissions and increased healthcare costs.6 In Sweden and abroad, 10 
different initiatives have been taken in the past decades to improve medication 11 
prescribing and decrease inappropriate polypharmacy, such as the introduction of 12 
regulatory policies, computerised support systems, healthcare professional education 13 
and interventions at patient level.7,8 One of these interventions is the performance of a 14 
medication review, a structured, critical examination of a patient's medications to 15 
optimise the impact of medications and minimise medication-related harm.9 Healthcare 16 
interventions, like medication reviews, are often successfully conducted in a research or 17 
project setting, but the implementation and embedding in clinical practice is 18 
challenging.3,10  19 
In 2015, a European Union (EU) co-funded project, ‘Stimulating Innovation 20 
Management of Polypharmacy and Adherence in the Elderly (SIMPATHY)’ 21 
commenced, with the aim to stimulate, promote and support innovation across the EU in 22 
the management of appropriate polypharmacy and adherence in older patients.11 One of 23 
the key activities of SIMPATHY was the performance of case studies in 8 European 24 
countries: Germany, Greece, Italy, Poland, Portugal, Spain, Sweden and the United 25 
Kingdom (UK).12 The aim of these case studies was to address what existed regarding 26 
polypharmacy management in the EU; why programmes were, or were not, developed; 27 
and, how identified initiatives were developed, implemented, and sustained. These 28 
questions were answered in each country through individual case studies of national or 29 
regional programmes. Framework analysis across all cases found that polypharmacy 30 
management was not consistently addressed within the studied EU countries, but it 31 
provided examples of initiatives that could assist managers and policymakers in 32 
developing or scaling up programmes.12 33 
One of these examples was the case study in Sweden. In past decades, the focus 34 
of the Swedish government has been on the quality of care in older patients. A national 35 
survey reported a threefold increase in the prevalence of polypharmacy, defined in the 36 
survey as the use of 5 or more medications, from 18 % in 1992 to 42 % in 2002.13 In the 37 
following years, the government took several measures to improve the quality of care in 38 
older patients, such as the development of quality indicators and the funding of different 39 
programmes.14,15 The prescribing of inappropriate medication in older patients 40 
decreased by 36 % between 2006 and 2012 in persons aged 80 years and older,15 but the 41 
issue of inappropriate polypharmacy remained.16 Despite the national focus on the care 42 
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for older people, a formal programme on polypharmacy management was never 43 
developed. 44 
Region Uppsala, one of the twenty self-governing regional authorities in 45 
Sweden, implemented the performance of medication reviews by clinical pharmacists, 46 
in the context of the national focus on the care for older people. These pharmacists work 47 
in multiprofessional healthcare teams in either hospitals, nursing homes or primary care 48 
centres, and they specifically address polypharmacy in older patients. Swedish and 49 
international studies have shown that medication reviews by clinical pharmacists 50 
increase appropriate prescribing and medication use,7,17 which may prevent hospital 51 
visits and unnecessary healthcare costs.18 Other regional authorities have also 52 
introduced clinical pharmacists in healthcare teams, but this has developed 53 
heterogeneously throughout the country. Region Uppsala currently has the highest 54 
number of clinical pharmacists per capita in the country, and the demand is growing. It 55 
is unknown what exactly has led to this seemingly successful implementation at 56 
regional level. An in-depth understanding of the different factors involved and what 57 
actions need to be taken for successful implementation and sustainment in practice, may 58 
support future polypharmacy programmes.  59 
To get a better understanding, the Swedish case was adapted study after 60 
publication of the 8 SIMPATHY case studies12: the scope was changed from a national 61 
level (Sweden) to a regional level (Region Uppsala), and incomplete findings were 62 
supplemented with additional data. We therefore present the updated Swedish case 63 
study, which aimed to explore the events, actions and other factors that were involved in 64 
the implementation and sustainability of medication reviews in older patients by clinical 65 
pharmacists in Region Uppsala. 66 
Methods 67 
Design and underlying theories 68 
This study used a case study design.19 The unit of investigation was the process of 69 
implementation and sustainment of the performance of medication reviews by clinical 70 
pharmacists. Events, actions and other factors involved in this process were explored.  71 
Multiple useful theories and models exist that can be applied for understanding a 72 
process of implementation and integration in daily practice. In this study, Kotter’s 8 73 
Steps Process for Leading Change (Kotter) and Normalization Process Theory (NPT) 74 
were used.20,21 Kotter is a change management model which uses a nonlinear 8 step 75 
approach: create a sense of urgency, build a guiding coalition; form a strategic vision 76 
and initiatives, communicate the vision, enable action by removing barriers; generate 77 
short term wins; sustain acceleration; and institute change.20 NPT is a sociological tool, 78 
consisting of 4domains, that has been used to evaluate implementation processes in a 79 
broad range of complex health care practices.22–24 Combined, Kotter and NPT provide 80 
rigorous support to explore the chosen processes. 81 
Setting 82 
This case study focussed on Region Uppsala, previously known as Uppsala County 83 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Council. Healthcare in Sweden is largely financed by local taxes and Region Uppsala is 84 
responsible for the quality of and access to healthcare for all 360 000 inhabitants in 85 
Uppsala County.25 It owns and operates the 2 hospitals in the county, Uppsala 86 
University Hospital and the hospital in Enköping, and roughly half of the county’s 87 
primary healthcare centres.26 Since 2012, all clinical pharmacists conducting medication 88 
reviews in the county have been employed by Region Uppsala. Previously, these 89 
pharmacists were employed by the state-owned pharmacy company Apoteket AB, 90 
which held a national monopoly on the sale of medications until 2009. This case study 91 
therefore also explored Apoteket AB’s role in the implementation process. External 92 
events, actions and other factors which have influenced the implementation of 93 
medication reviews by clinical pharmacists in Region Uppsala were also part of the 94 
scope of this case study. Two national organisations were therefore specifically 95 
included: the Swedish Association of Local Authorities and Regions (SALAR), which 96 
represents the interests of all regional and local authorities in Sweden, and the National 97 
Board of Health and Welfare (Socialstyrelsen), a government agency under the Ministry 98 
of Health and Social Affairs. There was no specific time frame for this study, but it 99 
included data up to 2015. 100 
Data generation and analysis 101 
Literature review 102 
A literature review was performed by 2 researchers (TK and UG) between September 103 
2015 and December 2015 to identify documents relevant to this case study. One 104 
researcher (TK) was a recent graduated pharmacist and research assistant, and the other 105 
(UG) was a senior clinical pharmacist and researcher, responsible for the development, 106 
implementation and evaluation of clinical pharmacy services in Region Uppsala. The 107 
researchers used a guide with questions to structure the review process, specifically 108 
developed for all SIMPATHY case studies (Supplementary appendix). Questions were 109 
drawn from Kotter to inform assessment of change management strategies, and from 110 
NPT to inform the integration in daily practice. Google search, MedLine database and 111 
Region Uppsala’s intranet were used to collect peer-reviewed publications and grey 112 
literature, such as policy documents and guidelines. Relevance of the documents was 113 
determined through consensus by the 2 researchers.  114 
Semi-structured interviews 115 
After the literature review, semi-structured interviews were held with key informants 116 
who had been influential to the implementation of medication reviews by clinical 117 
pharmacists. The sampling strategy was to recruit informants from different positions 118 
and institutions. Targets for recruitment included at least one policy maker, a manager 119 
responsible for implementation, and a healthcare professional. Potential informants 120 
were either authors of or mentioned in documents identified in the literature review. 121 
Four informants were eventually approached, either by mail or telephone, and agreed to 122 
participate. The interview guide was based on principles from Kotter and NPT, see 123 
Supplementary appendix. It addressed the rationale for the introduction of medication 124 
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reviews; implementation strategies; integration into daily practice; evaluation; and, 125 
plans for future developments. The interview topics were fixed, and questions were 126 
modified for each informant based on the role of the informant. The 2 local researchers 127 
(TK and UG) received both in-person and web-based training by researchers 128 
experienced in qualitative research (DS and others) and one of the SIMPATHY case 129 
study coordinators (JM) on using the guide, and on conducting and analysing interviews 130 
and focus groups in general. Together they performed the 4 interviews in November 131 
2015 and December 2015, which lasted between 50 and 80 minutes. All informants in 132 
this case study provided written informed consent prior to their participation. The 133 
Regional Ethical Review Board in Uppsala was consulted, and the study was exempted 134 
from ethical approval as it did not involve sensitive personal data according to the 135 
Swedish Personal Data Act (1998:204). 136 
Data analysis and integration of the literature review and interviews 137 
The interviews were audio-recorded, transcribed and thematically analysed using a 138 
deductive coding framework based on Kotter and NPT. The 2 local researchers first 139 
independently coded the interviews, and then consensus was sought in case of 140 
conflicting results. A summary of the documents identified in the literature review and 141 
analysis of the interviews were combined into a summary report. 142 
Focus group triangulation 143 
To confirm the trustworthiness of the findings in the summary report and identify any 144 
gaps or weaknesses in the report, a focus group was conducted in February 2016 at 145 
Uppsala University Hospital. Participant sampling and recruitment followed the same 146 
process as the key informant interviews. Informants who had been interviewed were 147 
eligible for inclusion, but other experts were also recruited. Eight informants (3 of 148 
whom had been interviewed) were asked for participation and agreed to participate. The 149 
informants received the summary report one week in advance of the focus group session 150 
with the request to assess it for correctness and completeness. Two informants were 151 
eventually unable to participate due to practical reasons and they provided written 152 
feedback. The focus group was run by one moderator (UG) and one note taker (TK) and 153 
lasted for 120 minutes. The moderator used a topic guide developed by the SIMPATHY 154 
study coordinators (Supplementary appendix). It included questions about how the 155 
results in the summary report matched with personal experience and knowledge, if there 156 
were any points that had been missed or not emphasized enough, and if there was 157 
anything incorrect.  158 
Additional literature review and interviews 159 
The initial literature review, semi-structured interviews and focus group triangulation 160 
were part of the original SIMPATHY case study.12 Agreement with specific findings 161 
was expressed throughout the focus group session, but some areas needed more detail. 162 
To address these areas, 3 additional interviews were conducted. Two focus group 163 
participants were asked specific questions to elaborate on their input during the focus 164 
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group session, and a third key informant was recruited to go into detail about policy 165 
decision-making within Region Uppsala. The informants were asked to focus on the 166 
period up to 2015 to be consistent with previous data generation and analyses. The 167 
interview guide for this third interview was based on the same one used for the previous 168 
semi-structured interviews (Supplementary appendix). The interviews were performed 169 
by a Master’s thesis pharmacy student (MF) who received training in qualitative 170 
interviewing by one of the other local researchers (TK). All informants were either 171 
approached by e-mail or telephone. Interviews were performed in March 2018 and 172 
lasted 20-40 minutes. The literature review was updated on missing documents based on 173 
specific input from the focus group and additional interviews. Literature covering 174 
events, actions or other data after 2015 was excluded. Four documents were eventually 175 
added.27–30 176 
Final data analysis 177 
The focus group discussion and additional interviews were audio-recorded, transcribed 178 
and thematically analysed by 2 researchers (MF and TK) using the same method as with 179 
the first key informant interviews. Events, actions and other factors that were identified 180 
using the Kotter’s principles, and which overlapped with identified factors using NPT, 181 
were integrated in the final analysis.  182 
Results 183 
In total, 6 physicians, 3 pharmacists and 1 nurse, all with different specialisations and 184 
positions within national and regional institutions, participated in the case study. Table 185 
1 presents the profession, relevant position at the time of participation and the role of 186 
the key informants in this case study. 187 
Table 1. Key informants’ profession, position and participant role in the case study. 188 
Key informant Interview 
(I) 
Focus group 
(F) 
Additional 
interview (A) 
1. Physician, former chairperson of the DTC, 
Region Uppsala 
X   
2. Physician, expert on pharmacotherapy in older 
patients, Socialstyrelsen 
X X  
3. Physician, chief project leader for the Be-Life 
programme, SALAR 
X *  
4. Clinical pharmacist, project leader within the Be-
Life programme, SALAR 
X *  
5. Physician, former head of medicine, Uppsala 
University Hospital 
 X  
6. Clinical pharmacist, internal medicine, Uppsala 
University Hospital 
 X  
7. Physician, PhD candidate on inappropriate 
prescribing, Karolinska Institutet, Stockholm 
 X  
8. Pharmacist, chief pharmacist, Uppsala University 
Hospital 
 X X 
9. Physician, chairperson of the DTC, Region  X X 
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* This informant only provided written feedback on the summary report.  189 
DTC = drug and therapeutics committee; SALAR = Swedish Association of Local Authorities and 190 
Regions 191 
The factors identified within this case study as either the presence (facilitators) 192 
or the absence (barriers) of Kotter’s principles and NPT domains, are presented in Table 193 
2. The findings are structured according to these principles and domains. It refers to 194 
documents from the literature review and is supported by quoted phrases from key 195 
informants expressed in either the initial interviews (I1-4), the focus group (F2-9) or the 196 
additional interviews (A8-10). A time line of specific events, actions and publications 197 
which are mentioned in the text, is shown in Figure 1 at the end of the results section. 198 
Table 2. Events, actions and other factors involved in the implementation and sustainability of 199 
medication reviews by clinical pharmacists in Region Uppsala, identified within this case study 200 
as either the presence (facilitators) or the absence (barriers) of Kotter’s principles and the 4 201 
Normalization Process Theory (NPT) domains. 202 
Kotter (1-8) and NPT Facilitators Barriers 
Create a sense of 
urgency (1) 
- Evidence on inappropriate 
polypharmacy 
- National focus on quality of care for 
the elderly 
 
Build a guiding 
coalition (2), and 
cognitive participation 
(NPT) 
- Multiprofessional collaboration  
- Key individuals to drive change 
- Support from stakeholders 
- Lack of team setting in primary care 
- Scepticism towards physician-
pharmacist collaboration 
Develop a vision (3), 
communicate the 
vision (4), and 
coherence (NPT) 
- National vision for quality of 
medication in older patients 
- Regional vision for pharmacists 
within healthcare 
- Local leadership and networking at 
national level 
- Public involvement 
- Lack of national plan for 
implementation of medication 
reviews 
- Unclear allocation of tasks and 
responsibilities 
- Lack of belief in the need for 
medication reviews 
Enable action by 
removing barriers (5), 
and collective action 
(NPT) 
- Education for healthcare 
professionals 
- Financial support and pay-for-
performance 
- National legislation and guidance on 
medication reviews 
- Shared electronic medical records 
and prescribing tools 
- Lack of time and continuity in 
healthcare 
Generate short-term 
wins (6), and reflexive 
monitoring (NPT) 
- Periodical reports on quality 
indicators 
- Local evidence on the effects of 
medication reviews 
- Lack of national monitoring and 
evaluation 
Uppsala 
10. Nurse, former chief pharmaceutical officer, 
Region Uppsala 
  X 
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Sustain acceleration 
(7), and institute 
change (8) 
- From project funding to permanent 
positions 
- Continual monitoring and 
development plans 
- Focus shifting away from care for 
the elderly 
- Deregulation of the state's pharmacy 
monopoly 
 203 
Create a sense of urgency (1) 204 
Evidence on inappropriate polypharmacy 205 
The issue of inappropriate prescribing among older patients was “first acknowledged in 206 
the 1980s in Sweden, following the first publications and attention from the USA” (I1). 207 
In the 1990s, studies within Sweden also showed that older patients made extensive use 208 
of medications, often prescribed without sufficient regard for quality.14,31,32 In 2000, the 209 
government commissioned Socialstyrelsen to develop a list of quality indicators with 210 
the purpose to monitor and improve the quality of prescribing in older patients. The 211 
indicators were based on earlier lists from North-America,33,34 and the first version of 212 
the list was released in 2004.35 General quality indicators for care for the elderly were 213 
published in 2009, and 2 of those indicators addressed the need for medication 214 
reviews.36 215 
National focus on quality of care for the elderly 216 
In the Swedish healthcare system, “the government defines the [general] direction and 217 
at the beginning of the century there was much focus on the care for the elderly” (I3). 218 
The need to improve the quality at national level supported initiatives at regional level 219 
as well. Around 2009, the sense of urgency was increased by stories of patient cases that 220 
got national media attention. 221 
Build a guiding coalition (2), and cognitive participation (NPT) 222 
Multiprofessional collaboration 223 
One of the first studies in which medication reviews were conducted by clinical 224 
pharmacists in Sweden was in 1994-1995.29 The study was a collaboration between the 225 
state-owned national pharmacy chain, Apoteket AB, and Socialstyrelsen. It involved 226 
pharmacists present at nursing homes including direct contact with physicians and 227 
nurses. The use of inappropriate medications decreased in the participating nursing 228 
homes and 80% of the healthcare professionals wanted to continue the collaboration 229 
with the pharmacist.29 In 2001, another influential study was performed in which 230 
clinical pharmacists were added to the emergency department team of a hospital in 231 
southern Sweden.28 This concept of having multiprofessional collaboration was also 232 
seen as a facilitator in Region Uppsala: “It is important to stress out the teamwork […] 233 
Pharmacists joined the ward rounds which really benefited the healthcare process.” (F5) 234 
Key individuals to drive change and support from stakeholders 235 
“The multiprofessional collaboration and certain key individuals in Uppsala were 236 
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success factors for the development.” (F8) These key individuals had different 237 
professional backgrounds (medicine, nursing, pharmacy) and some held influential 238 
positions, such as the head of medicine at Uppsala University Hospital. They managed 239 
to get the support from other stakeholders, such as the Regional Office, Apoteket AB 240 
and influential members of the drug and therapeutics committee (DTC). 241 
Lack of team setting in primary care and scepticism towards physician-242 
pharmacist collaboration 243 
The successful collaboration that was seen at hospital wards was harder to establish 244 
within primary care. There is less experience with multi-professional collaboration, 245 
because “in primary care you usually only have the general practitioner working alone” 246 
(F7). Scepticism towards collaboration with pharmacists existed among physicians: 247 
“Many physicians […] were quite negative towards clinical pharmacists.” (A10) 248 
However, this can change as one clinical pharmacist stated: “The sceptical physicians I 249 
have met were usually very positively surprised with our input” (F6). 250 
Develop a vision (3), communicate the vision (4) and coherence (NPT) 251 
National vision for quality of medication in older patients and regional vision for 252 
pharmacists within healthcare 253 
In 2010, representatives from different governmental organisations, professional bodies 254 
and the pharmaceutical industry took part in the formation of a strategy of dealing with 255 
the challenges regarding medication use in Sweden.37 Among the prioritized domains 256 
was the performance of medication reviews. In Region Uppsala, it was important “to 257 
point out that the national medication strategies mentioned medication reviews as well” 258 
(F8). 259 
Local leadership and networking at national level, and public involvement 260 
The vision in Region Uppsala was communicated through local leaders who tried to 261 
influence institutions at national level through networking. Public involvement also 262 
became an important driver for change: “There has been a great involvement of patients 263 
and pensioners, and this public engagement has definitely made a difference.” (F9) 264 
Lack of national plan for implementation of medication reviews and unclear 265 
allocation of tasks and responsibilities 266 
Although medication reviews became a part of the national medication strategy,37 there 267 
was no national plan for implementation. Next to that, the unclear allocation of tasks 268 
and responsibilities concerning medication reviews was a barrier. One expert from 269 
Socialstyrelsen mentioned that “there were great differences among healthcare 270 
professionals on the view of how and by whom these [medication review] activities 271 
should be performed” (I2) and in primary care it is often unclear “who has the 272 
responsibility if a certain medication has been initiated in hospital” (F7). 273 
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Lack of belief in the need for medication reviews 274 
Another critique expressed by some physicians was the lack of need to perform 275 
medication reviews “if you prescribe correctly from the start” (I4). 276 
Enable action by removing barriers (5) and collective action (NPT) 277 
Education for healthcare professionals 278 
A key enabler to drive the performance of medication reviews has been education. In 279 
the late 1990s, the Swedish Pharmaceutical Society financially supported Swedish 280 
pharmacists to attend a clinical pharmacy programme in the UK. When these 281 
pharmacists returned, they started working at different healthcare settings in the 282 
country. In 2001, a ten-week long undergraduate clinical pharmacy course was started 283 
at Uppsala University, and “2006 was a very important year, because of the start of the 284 
[post-graduate] clinical pharmacy programme” (I1). Both courses had been inspired by 285 
the programmes in the UK. Education on prescribing and medication use in older 286 
patients was also developed for physicians and nurses.  287 
Financial support and pay-for-performance 288 
Financial support for innovation and development from different actors has been 289 
essential. From 2001, the state-owned Apoteket AB financed positions from clinical 290 
pharmacists within Region Uppsala. Some positions were also financially supported by 291 
Region Uppsala through “some extra development funding” (A10). Financial support 292 
from the Swedish Pharmaceutical Society was used for study visits and research 293 
projects throughout the years. In 2007-2012 the national government decided to allocate 294 
approximately € 500 million, which regional authorities could apply for, to improve the 295 
quality of care for the elderly.15 One of the 7 prioritized domains was the performance 296 
of medication reviews, which eventually made up 8% (€ 40 million) of the total budget. 297 
Region Uppsala successfully applied for funding for clinical pharmacists, among other 298 
things. For the period 2010-2014, SALAR and the government carried out an extensive 299 
national programme to improve the quality of care for older people in Sweden, called 300 
‘A better life for elderly sick people’ (Be-Life) programme.38 The programme used a 301 
pay-for-performance model in which financial incentives were provided to regional 302 
authorities for improving their scores on the quality indicators. Medication reviews 303 
were “not really an important part of the Be-Life programme” (I4), but they were 304 
suggested as one of multiple ways to improve indicator scores. In total, the Be-Life 305 
framework agreement comprised of approximately € 400 million.38 306 
National legislation and guidance on medication reviews 307 
In 2012, Socialstyrelsen updated existing legislation on medication management,39 308 
which included statements about medication reviews for patients aged 75 years or older 309 
with 5 or more medications.39 In 2013, Socialstyrelsen also developed a guidance on 310 
how to perform these medication reviews.40 In Region Uppsala, specific routines were 311 
based on the national legislation and guidance.41  312 
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Shared electronic medical records and prescribing tools 313 
ICT developments in the past decades have made it possible for the clinical pharmacists 314 
in Region Uppsala to record the findings of the medication reviews in the patients’ 315 
electronic medical records, which are accessible to most of the healthcare professionals 316 
within the county. In the primary care setting, pharmacists and physicians make use of 317 
the locally developed PHASE-20 symptom rating scale.42 The tool can be used to 318 
identify symptoms in patients that can be related to their medications. Next to that, the 319 
DTCs of several collaborating regions, including Region Uppsala, published a guideline 320 
on medication therapy for frail older patients in 2013, which is updated biannually.43 321 
Lack of time and continuity in healthcare 322 
Lack of time and continuity have been barriers that still exist in both primary and 323 
secondary care. Physicians lack time to discuss patient cases with the pharmacist. 324 
Medication reviews generally also need follow-up but “patients often lack a permanent 325 
physician, so the effect of the reviews gets lost” (A9). 326 
Generate short-term wins (6) and reflexing monitoring (NPT) 327 
Periodical reports on quality indicators 328 
Provision of annual and monthly national quality indicator scores35,36 by SALAR to 329 
regional authorities has made it possible “to see the improvement in the indicators, 330 
and it was especially clear when it concerned medication prescribing.” (F9)Region 331 
Uppsala has integrated most indicators in annual pay-for-performance agreements 332 
with hospitals and primary care centres.30 Additional income is gained if more 333 
medication reviews have been performed in patients 75 years or older than the 334 
previous year. 335 
Local evidence on the effects of medication reviews 336 
In 2005-2006, an RCT was conducted at 2 internal medicine wards at Uppsala 337 
University Hospital, based on a successful model to perform medication reviews from 338 
Northern Ireland.27 In this RCT, patients aged 80 years or older who received such 339 
medication reviews, had 16 % less hospital visits and approximately € 200 lower 340 
hospital-based costs during 12-month follow-up compared to control patients.44 The 341 
study received a lot of attention within Sweden and abroad. “With the study, it became 342 
easier to sell the idea [of medication reviews by clinical pharmacists] to the medical 343 
profession” (A10). Similar ways to perform medication reviews by clinical pharmacists 344 
have been introduced in other parts of Sweden as well.28,45 In 2011, an RCT performed 345 
in the south of Sweden showed a decrease in inappropriate medication use and 346 
medication-related hospital visits.45 However, evidence based on international literature 347 
remained inconclusive regarding clinically important outcomes.46,47 348 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Lack of national monitoring and evaluation 349 
Although medication reviews were mentioned in the national medication strategy and 350 
specific legislation and guidance was developed, there has been no monitoring or 351 
evaluation of their impact from a national perspective.  352 
Sustain acceleration (7) and institute change (8) 353 
From project funding to permanent positions, continual monitoring and 354 
development plans 355 
In recent years, project funding of clinical pharmacists has been replaced by permanent 356 
positions incorporated in annual budgets, mainly within Uppsala University Hospital. 357 
The quality indicators have been continually used at national and regional level, to keep 358 
improving the quality of prescribing. A new multicentre RCT to investigate different 359 
medication review models has been planned, and plans exist to create more clinical 360 
pharmacist positions in primary care, which “shows that the interest [in primary care] 361 
exists and that the pharmacists have established themselves out there” (I9). 362 
Focus shifting away from care for the elderly, and deregulation of the state's 363 
pharmacy monopoly 364 
With other issues dominating politics, “such as a high number of incoming refugees, the 365 
focus is not on the care for elderly anymore. There is actually not much planned at this 366 
moment, due to the different political landscape” (I2), which may be a barrier for large-367 
scale implementation in Uppsala county and at national level. Deregulation of the state's 368 
pharmacy monopoly in 2009 has made collaboration within Region Uppsala more 369 
complex, as more actors are currently involved. Previously, it was “easier to steer 370 
questions concerning medications and management” (A8).  371 
 372 
[Please insert Figure 1 here] 373 
 374 
Figure 1. Time line of specific events, actions and publications involved in the implementation 375 
and sustainability of medication reviews by clinical pharmacists in Region Uppsala. RCT, 376 
randomised controlled trial; SALAR, Swedish Association of Local Authorities and Regions 377 
Discussion 378 
This case study identified multiple events, actions and other factors that have been 379 
involved in the implementation and sustainability of medication reviews in older 380 
patients by clinical pharmacists in Region Uppsala: from the recognition of 381 
inappropriate prescribing and polypharmacy in the 1980s until the creation of 382 
permanent clinical pharmacist positions in recent years. Factors were identified across 383 
all Kotter’s principles and NPT domains, even though a formal change management or 384 
systems approach48 was never used. Successful implementation usually requires an 385 
active change process, but this process may be an interrelated series of sub-processes 386 
that do not necessarily occur sequentially or have been formally planned.49 In this case 387 
study, the facilitating processes were mostly uncoordinated and nonlinear, but they all 388 
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promoted medication reviews at different levels within the healthcare system.  389 
The findings confirm the complexity of factors necessary for successful 390 
implementation as addressed by existing implementation frameworks.49,50 These 391 
frameworks generally distinguish between the outer and inner context, the individuals 392 
involved, the innovation itself, and the facilitation process. Essential factors related to 393 
the outer context were the focus of the national government on improving the care for 394 
older patients, including the role of quality indicators, legislation and financial support, 395 
and involvement of the public and media. These factors seem to have promoted a 396 
culture of innovation at a national level. In organisational science, customer (or patient) 397 
focus, teamwork with others and appropriate resources are the 3 top ranked factors for 398 
developing an innovative culture.51 In Kotter’s terms, it helped to create a sense of 399 
urgency, build a guiding coalition and enable action by removing barriers. Within this 400 
context, key individuals and local leaders from different healthcare professions were 401 
able to initiate and fund projects within Region Uppsala where clinical pharmacists 402 
were added to existing healthcare teams to conduct medication reviews. Through these 403 
projects within the region, evidence was produced which strengthened the view of 404 
medication reviews as an effective intervention. Specific under- and postgraduate 405 
education for clinical pharmacists and other healthcare professionals, and ICT 406 
developments have been main facilitating factors alongside this process.  407 
These findings are similar to the themes identified within the cross-case analysis 408 
of polypharmacy programmes within the SIMPATHY project.12 Another common 409 
theme is the definition of roles and responsibilities. Uncertainty around this theme was 410 
seen as a barrier in our case study, which is typical for qualitative studies on the 411 
collaboration between physicians and pharmacists.52–55 Healthcare professionals need to 412 
understand their specific tasks and responsibilities around a set of practices (a 413 
component of coherence, NPT).21 Current legislation states that the physician is 414 
responsible for conducting medication reviews,39 but it is unclear how this relates to the 415 
involvement of pharmacists. Introducing new roles in healthcare puts pressure on 416 
professional boundaries and generates fundamental questions concerning 417 
professionalism and remuneration.56 In response, established professionals may seek to 418 
protect and maintain boundaries, which in this case can give rise to scepticism towards 419 
physician-pharmacist collaboration. Professional boundaries hinder multiprofessional 420 
collaboration 57 and changing roles requires changing the system at various levels.56 Our 421 
study and previous research 58 indicate that scepticism within individuals may disappear 422 
after the start of collaboration. However, not only individual and organisational redesign 423 
is required for sustainability, but also the reframing of professional roles and 424 
responsibilities at higher layers of the healthcare system. The findings in this case study 425 
and those from a qualitative study in primary care practices in Stockholm County 59 426 
suggest that this may be even more difficult in primary care, due to the lack of 427 
continuity, time and a multiprofessional team setting. Other important barriers that 428 
hindered large-scale implementation within the region and beyond were a lack of 429 
implementation, monitoring and evaluation by a national institution and the political 430 
focus shifting away from care for the elderly to other issues. 431 
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Strengths and limitations of the study 432 
Different strengths of this study ensure trustworthiness of its findings. First, a case study 433 
is a reliable method to provide a deeper understanding of a process within an 434 
organisation.19 Data was combined from different sources, triangulated the findings 435 
through a focus group session, and supplemented incomplete findings with additional 436 
data, which increases credibility. 60 Existing change management and implementation 437 
theories 20,21 were used to generate and analyse data after providing training to the local 438 
researchers, and established guidelines 61,62 were used to report the findings. Key 439 
informants from all relevant levels and professions were recruited and all agreed to 440 
participate. One of the local researchers (UG) was a key individual within this case 441 
study, having been involved in the performance of medication reviews in Region 442 
Uppsala since 2001, and was able to identify these key informants and essential 443 
documents for the literature review. 444 
This also poses a risk of bias in terms of data generation and interpretation. All 445 
researchers have a professional background in pharmacy, which may impact 446 
confirmability.60 We tried to mitigate this by involving other professions in the 447 
triangulation process, providing more variety of perspectives. Another limitation of this 448 
case study is the specific focus on Region Uppsala, which may limit transferability to 449 
other regions and other countries with different healthcare systems. However, we 450 
managed to identify specific factors in the context of generic change management and 451 
implementation principles and related these findings to research within different 452 
contexts.  453 
Implications for practice and future initiatives 454 
This study contains important factors to consider in future initiatives to implement 455 
medication reviews by clinical pharmacists, both in Sweden and abroad. Future research 456 
should be designed to help us better understand the criticality of these factors. Our 457 
findings suggest the need for a systems approach using change management or 458 
implementation theory. Planning and coordination of a theory driven approach may not 459 
be necessary, but it can promote acceleration of change and anticipation on expected 460 
barriers. Examples of specific factors to consider within such an approach are 461 
multiprofessional collaboration in both the intervention and the implementation process, 462 
and education and training.  The roles and responsibilities of all involved healthcare 463 
professionals should also be clearly defined, addressing time allocation and continuity 464 
in healthcare for older patients.  465 
Conclusions 466 
Multiple factors across the full range of change management and implementation 467 
principles were involved in the implementation and sustainability of medication reviews 468 
in older patients by clinical pharmacists in Region Uppsala. This case study presents 469 
important factors to consider in similar initiatives in the future, both in Sweden and 470 
abroad. 471 
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Figure 1. Time line of specific events, actions and publications involved in the implementation and 
sustainability of medication reviews by clinical pharmacists in Region Uppsala. RCT, randomised 
controlled trial; SALAR, Swedish Association of Local Authorities and Regions 
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Supplementary appendix 
SIMPATHY Data collection tools 
 
Data sources 
Data collection for case studies usually consists of a range of sources, commonly including 
archival information, interviews, and direct observation. SIMPATHY case study data collection 
will consist of three phases: a desk review, key informant interviews, and focus groups.  
Information on inclusion criteria and specific collection procedures are included in the 
individual sections.  Below is a brief summary of each source.  Of note, although direct 
observation would have provided significant insight into how a polypharmacy programme is 
truly operating, this would require resources beyond those available at the moment and 
therefore will not be used for this project. Desk review 
The primary focus of the desk review is to articulate the specific activities that take place as 
part of the polypharmacy programme.  It will also provide an overview of the healthcare 
system and institutions within each case study, and describe some of the legislative or policy 
structures in place that support the polypharmacy programme.  Existing public and internal 
documents will provide the data for this portion of the case study.   Key informant interviews 
A second data source is the key informant interviews.  Interviews will be used to add depth to 
the information collected in the desk review, while also providing insight into the 
development, implementation, and maintenance of the programme.  The interviews will shed 
light on topics not specifically addressed in published documents, especially regarding 
management and leadership strategies to develop and sustain the programme.  Some 
questions covered in the desk review may also be addressed in the interviews.  Although we 
have attempted to minimize redundancies between the desk review and interviews, in some 
situations it is good, or even necessary, to utilize different data sources to look at the same 
issue in order gain a more accurate understanding the question at hand. Focus groups 
The third data source will be focus groups of patients, health care providers, and policy 
makers.  The focus groups will be used to validate the findings generated be the desk review 
and key informant interviews.  These discussions should let the research team know if their 
findings accurately reflect the experience of patients and practitioners in a real world setting. 
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Desk Review 
Completing the desk review 
The research team 
The initial phase of the case study is a desk review of policies and procedures outlining your 
polypharmacy programme.  Almost all of these documents will be considered grey literature, 
and some may be internal working documents that are not available to the public.  Therefore, 
it will be necessary for each case study team to identify a senior clinician (physician, 
pharmacist, nurse, etc.), policy maker, or both who is familiar with the development and 
implementation of the programme to assist with identifying relevant documents.  This may be 
a member of the SIMPATHY research team, or may be someone from outside of the project, 
depending on the makeup of your current research team and the polypharmacy and 
adherence programme that you use for the case study.  Identify one or two people who will 
assist in the desk review. 
Documents to include 
The desk review should be completed utilizing existing published or internal documents.  
Include all policies that currently govern activities within your programme.  Depending on the 
structure of your health care system, this may include national, regional, or local policies.  In 
addition to publicly available documents, you may also include presentations, institutional 
policies, or published literature that describes the programme.  All documents should be 
referenced appropriately with links to the original if available. 
Time frame  
There is no limitation on the publication date of documents.  That being said, all documents 
included should apply to the programme in its present form, so if more than one version of a 
policy is available, use the most recent version for the majority of the desk review.  The only 
time an older version might also be used is to illustrate the time frame for developing the 
polypharmacy programme.  In this case, older versions of a policy should be noted, but the 
content of the most recent version should be used. 
Research Personnel Examples 
 
Case Study from Spain 
Senior Clinician: Carles Codina is the head of the pharmacy departments in both the 
Hospital Clinic and the Vic University Hospital.  He has a working knowledge of both the 
government and institutional policies and procedures that guide the polypharmacy 
programmes in Barcelona and Vic.  Therefore, no additional personnel outside of the 
SIMPATHY team are required to complete the desk review. 
 
Research Staff: Jennifer McIntosh is a contracted pharmacist who will complete the desk 
review utilizing publicly available documents and those provided by Carles Codina. 
 
Example case study from Scotland 
Senior Clinicians: Alpana Mair Deputy Chief Pharmacist for Scotland and Simon Hurding 
clinical lead for therapeutics for Scotland will undertake the desk review. They are 
responsible for advising on the policy at national level and also work with colleagues at 
NHS boards and have knowledge in order to gather the research data. 
 
Research Staff: Moira Kinnear is a senior researcher in an NHS board who will complete 
the desk review accessing information that is available at health board level.  
 
 
 
 
 
3 
 
Please note that you might not find every piece of information in the guide below in a written 
document.  That unto itself is potentially interesting information, especially if key messages 
such as the rationale for developing a programme are not clearly outlined in a published 
guideline on the topic.  Therefore, please note when you are unable to identify items below 
(instructions provided in the report template).Key informant interviews can also be used to 
identify or clarify topics in the desk review that are not addressed in published literature. 
 
Desk Review Guide 
Global issues 
The following questions refer to the general economic environment that surrounded the 
development of the polypharmacy programme.   
 
 
For countries without a mature or established polypharmacy programme, this section 
provides an opportunity to describe competing programmes influenced by their 
economic situation. 
 
• How did wider economic issues affect health policy in your country or region?  For 
example, did economics play a role in setting priorities for programmes to develop?  
Was cost containment or use of expensive medicines prioritised over other initiatives? 
• Did these wider economic issues have any effect on the management of polypharmacy 
or the development of polypharmacy management programmes? 
Healthcare system overview 
In this section please provide a description of the healthcare system in your country or region.  
This information can be addressed regardless of the presence or absence of a polypharmacy or 
adherence programme.  Please specifically address the following points: 
 
• Financing: Is the financing public, private, or mixed?  What type of out-of-pocket 
expenses are patients expected to cover? 
• Decision-making: Where are decisions made regarding healthcare spending and 
policy?  Is decision making devolved to local regions or is it centralized?  If there are 
multiple levels of policy (national, regional, local) how are these integrated? 
• Prescription medicines: How are prescription medicines financed? What is the role of 
community pharmacists in supplying medicines and how are they paid for this?  Do 
patients ever have access to prescription medications without a prescription? 
• Are pharmacists or others paid for advice on medicines at the point of supply? If so 
please describe including if there is any variation between practice settings (for 
example, if pharmacists in a primary care setting are reimbursed for counselling but 
community pharmacists are not). 
• Roles of healthcare providers: Who has authority to prescribe?  Are there different 
levels of provider status within professions (for example advanced practice nurse 
practitioners with prescribing authority)?  Which healthcare providers are involved in 
reviews of medication profiles?  In patient education? 
• Policy: What policy is in place that supports the polypharmacy programme?  If no 
polypharmacy programme is in place, briefly describe any other policies that influence 
medicines management. 
• Legislation: What legislation is in place that directly or indirectly supports the 
polypharmacy programme?  This might include items such as legislation defining who 
is a prescriber or mandating counselling on new prescription medicines.  If there is no 
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polypharmacy programme in place, describe how existing legislation would support or 
hinder implementation of a polypharmacy programme. 
Role of government  
In this section, please address the role of national, territorial or regional government policies as 
they relate to the development or implementation of polypharmacy and adherence policies.  If 
more than one level of government has authority or creates policies affecting the development 
and implementation of polypharmacy and adherence programmes include examples from each 
level. 
 
Please address the following points in your description: 
• Are there official policies or programmes at the government level regarding 
polypharmacy and adherenceprogrammes that govern activities within your case study 
boundaries or support the polypharmacy programme? 
o Do these policies address polypharmacy, adherence, or both?  How are each 
defined by the policy? 
o How do the policies on polypharmacy and adherence fit within the larger goals 
of the healthcare system? 
• If no policies exist, describe where you looked to identify policies and what type of 
information you did find regarding medicines management in the elderly.  For 
example, in Spain the Ministry of Health does not provide specific guidance on 
polypharmacy, but they do mention that polypharmacy management should be a part 
of comprehensive primary care services. 
o Provide a brief description of the types of medicines management documents 
that are available in your case study region regarding chronic disease 
management and the elderly. 
• Why were the specific interventions introduced: What was the underlying rationale 
that set out the case for these interventions?  Is there a clearly articulated vision for 
the programme?  If there are no policies, what are the main priorities of the national 
health or local health system?   
• How is policy information sent to the healthcare providers for action, and what if any 
monitoring of implementation is there? For example, in Scotland it is sent by the 
government to the health board leads and chief executives that requires them to take 
action on implementation and then report back.  
• What incentives are in place (if any) for the implementation of these programmes?  
Are there any contractual requirements to provide polypharmacy reviews?  Pay for 
performance? 
• How is the impact of these policies measured?  Are there systems or structures in 
place to monitor and evaluate the programme? 
External organizations 
This section pertains to external organizations, such as health organisations andhealth boards 
responsible for healthcare provision, professional associations, scientific societies, licensing 
bodies, or other non-governmental organizations that may influence the development and 
implementation of polypharmacy and adherence programmes.  
 
• Are there other organisations outside of the government that play a role directly or 
indirectly establishing clinical protocols for polypharmacy and adherence within your 
programme? 
• Why have these organisations become involved in polypharmacy and adherence? 
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• If so, please specify the organisations and the role they play.  Specifically, provide the 
name, a description of their mission or activities and how they relate to polypharmacy 
and adherence programmes,their geographic scope (e.g. local or national) and how 
their activities interrelate with the institutions and government agencies that make up 
your case study. 
• If no current policies exist, what role would outside organizations potentially play in 
developing guidelines and protocols related to polypharmacy and adherence in the 
elderly?  Are there organizations working on related topics? 
Health information and technology Population Level Health Information 
• What types of population level health indicators are available relative to polypharmacy 
and adherence?  If a programme exists, how are these utilised (or not utilised) in your 
programme? 
o If so who has access to this data and why? 
o Specify if any of the systems referred to in the report are public or private. 
• Is there any monitoring of prescribing patterns and the national, regional, or local 
level? 
• Does the health system have the capacity to link patient specific data such as 
prescribed medications and comorbidities?  What data specifically are available and 
how have they (or can they) be used to evaluate the impact of the intervention?  At 
what level are the data available (city, county, regional, national)? 
• Is there national or regional monitoring of prescription medications already 
undertaken, and for what purpose (for example, monitoring the cost and volume of 
medicines or for research)?  Patient Records 
• Are patient records available electronically throughout the healthcare system?   
• Do individuals in different institutions have access to the same information? 
• Does each health care provider involved in polypharmacy management have access to 
the clinical patient records? 
• Do any health care providers have limited access to patient information (for example 
some community pharmacists might not have access to laboratory values)? 
• Do healthcare providers in the outpatient and inpatient have access to the same 
information?  Are electronic patient records integrated throughout different 
healthcare settings? 
• How are electronic patient records utilised in the polypharmacy and adherence 
programme? 
• Do patients have access to their data?  Are there any tools (such as aps for 
smartphones) to help them access their data? Electronic Prescribing 
• Does the health system utilize electronic prescribing? 
• Is there an electronic database of dispensed medications? 
• Who has access to prescribing and dispensing records? 
• How is electronic prescribing utilised in the polypharmacy and adherence programme? Integration and Future Plans 
• Describe in general how information flows between different electronic health 
information systems. 
 
 
6 
• What, if any, new electronic health information technologies will your health care 
system be adopting within the next 2-3 years and how will this affect the 
polypharmacy and adherence programme?  
Clinical Decision Aids 
• Do clinicians undertaking the medication reviews have access to clinical decision aids 
to aid in the selection of appropriate drug therapy? 
o If so, please describe the type of aid and how it is accessed (e.g. via smart 
phone, computer, etc.).    
• What if any impact does this have on policy? 
• Are any support tools available for patients? 
Institutional level  
The goal of the following section is to obtain a detailed description of the polypharmacy and 
adherence programme within your case study at the institutional level.  This should be 
completed for each institution included in the case study. 
 
 
Partners with small pilot programmes may have difficulty addressing all of these 
points in this section.  Regardless of the type of programme you have, please attempt 
to address each item below and make a note of any topics that you were unable to 
find. 
 
Why 
• Why were the specific interventions introduced: what was the underlying rationale 
that set out the case for these interventions? 
Where 
• Where does the intervention take place?  Please include a brief description of the each 
institution including: 
o Type of institution (primary care, tertiary teaching hospital, etc.) 
o Ownership and management (public, private, or mixture of both) 
o Urban or rural setting  
o Numbers of patients served* 
o Number of health care providers practicing at the institution* 
* If available, these data should also include the proportion of those 
patients and health care providers participating in or eligible for the 
polypharmacy programme.  For example, you may have a 600 bed hospital 
but only patients on the 30 bed geriatric unit are targeted for the 
polypharmacy programme.  Including both numbers will provide a better 
understanding of the resources devoted to the polypharmacy programme. 
What 
• Is there a definition of polypharmacy and adherence at your institution?   
• At the various institutions within your case study, are there policies or practice 
manuals in place regarding polypharmacy and adherence?   If your case study includes 
more than one institution, such as a hospital and long-term care facility, address if 
there is a policy for each individual institution.  If you have adopted guidelines, or 
based the development of your guidelines, on those from an outside institution such 
as a scientific society, please include that information here.  
• Specifics of the guidelines: 
o Does the guideline outline a clear drug review process?  If it does what is it? 
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o Does the guideline contain tools or advice to assist drug review? 
o If there are tools what are they (e.g. STOP STARTT)? 
o Does the guideline specify who should receive a polypharmacy review? 
o Does the guideline contain any specific information on high risk medications to 
target? 
o Does the guide contain any information on drug efficacy? 
o  Are there elements of the guideline that specifically seek to lead to a patient 
centred / patient specific review (if so what are they)? 
o Does the guideline make use of worked examples? 
• Were any training materials provided to staff prior to or during the development and 
implementation of the programme?If there were training materials what methods 
were used? Example might include written material, workshops, in-services, or online 
courses.  Are any of these training activities ongoing? 
• Is any information on the programme provided to patients?  This might include items 
such as in-person counselling, education on specific medications or written 
information on their medication plan.   
• Is any information, training, or support provided to carers? 
Who 
• Who provides the intervention?  Please specify if it is a multidisciplinary team(specify 
team members e.g. physicians, pharmacists, nurses, or other providers), an individual 
practitioner, or a mix of the two.  If the intervention occurs on more than one occasion 
(for example during a hospital admission and then in the primary care setting) specify 
who provides the intervention in each setting.   
• What is their expertise related to this polypharmacy? 
When and how much 
• When does the intervention occur? 
o In person, such as during hospital rounds, at discharge, or during a 
regularly scheduled primary care visit. 
o On the phone 
o Virtual setting 
o Other 
• How often does the intervention occur (e.g. once during hospital admission, on an 
ongoing basis during primary care visits).   Please describe both the frequency and 
the location of medication reviews. 
• Approximately how much health care provider time is spent on each intervention? 
How 
• How are patients selected to receive the intervention?  Criteria may include items 
such as age, number of prescription medications, number of comorbid 
conditionsor the complexity of patient (explain how complex patients are 
identified and defined), absence or presence of frailty (as defined by your 
institution or practice setting), high-risk medications, patients with potentially 
inappropriate prescribing,or a combination of the above.   
• Are patients at high risk of adverse events from the medicines prioritised for 
review? 
• What specific services are provided as part of the intervention?  Please provide a 
brief description.Examples of services include a medication profile review by a 
pharmacist or other health care provider, patient education, or team education.  
Please provide a description of each service. 
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• If a medication review is conducted, what were the goals of the review?General 
therapeutic review?  Medication reconciliation?  De-prescribing?  Assess 
adherence? 
• How is the information communicated to team members?  Examples of 
communication methods include at the point of decision making (for example as 
part of rounds), as part of multidisciplinary case conference or post decision 
making  such as with a fax or text message, written notes in medical chart with 
suggested changed or simply as an oral consult with the prescriber. 
• How is information communicated between different levels of care, such as 
between a nursing home and hospital? Or between primary and secondarycare or 
between health and social care? 
• How is information communicated to patients?  Examples include verbal 
counselling, written prescriptions or written medication plans. 
• Are pharmacists a part of the programme?  If so, in what way?  Please describe the 
practice settings of pharmacists involved in the programme (e.g. hospital 
pharmacists, community pharmacists, or pharmacists in general practice offices) 
• If pharmacists are involved, is any training or certification required for 
participation? 
Tailoring 
• Is the intervention designed to be individualised to specific patient needs?  If so, in 
what ways was it individualised?   
• How are the patient’s goals and therapy objectives incorporated into the review 
and subsequent care plan?  How is this documented? 
 
Outcome measures 
• Has the intervention been measured? 
o If so, how?  Examples might include efficacy outcomes such as the 
medication appropriateness index, markers of prescribing 
appropriateness, adverse drug events avoided, patient satisfaction, safety 
indicators such as hospitalizations avoided, or the efficiency or economic 
impact of the programme.  Include all types of outcomes that have been 
evaluated. 
o What system or structures exists for capturing intervention effects? 
• How much time was involved in the evaluation process?  Were additional staff 
required for the evaluation phase? 
• Has there been any evaluation of the programme published within the last five 
years in peer-reviewed publications?  Please include a PDF of the document. 
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Interview Guide 
 
Introduction 
Hello, my name is XX and I am from XXX.  Thank you for agreeing to be interviewed as a part of 
the SIMPATHY project—we appreciate you contributing your time to our work. 
As was explained in the introductory email, SIMPATHY is a consortium of 8 countries in the 
European Union with the goal of promoting innovation around polypharmacy and adherence 
programmes in older people.  As part of this project, we are conducting case studies in 
different countries to help us better understand what polypharmacy programmes do or do not 
exist, but also what facilitated or hindered the development, implementation, and 
sustainability of these programmes.  The goal of this interview is to learn more about the state 
of polypharmacy management and adherence in XX location. 
 
This interview should not last longer than an hour.  With your permission, we’d like to record 
the interview.  All of the recordings and the notes I take will be used exclusively in this study, 
and will remain anonymous and confidential. 
 
Before we start, may I ask you to sign this consent form that outlines the information that I’ve 
just explained?  Please take your time to read it before you sign. 
 
1) Do you have any questions before we begin? 
 
2)To begin with, can you give me a brief description of your role within [name of institution] 
and how and why you are involved in the polypharmacy programme [or medicines 
management policies]? 
• I want to be sure that we’re all talking about the same thing, so I´m going to define a 
few terms.  When I say medicines management, I’m referring to the entire process of 
how medicines are selected, procured, delivered, prescribed, administered and 
reviewed to optimise patient outcomes.  This not only includes clinical activities, but 
also the development of guidelines and policies to govern the process.  Inappropriate 
polypharmacy is when a patient is on multiple medications (usually five or more), and 
the risk of harm from those medicines outweighs the benefits.  Sometimes 
polypharmacy is appropriate and indicated, like when a patient has multiple chronic 
conditions, but many times it is not appropriate and can result in patient harm.  A 
polypharmacy management programme is a systematic medicines management 
programme focused on optimizing the drug therapy of patients on multiple 
medications.   
• Are you aware about the issue of inappropriate polypharmacy associated with 
multimorbidity? Do you think it affects you? Why (or why not) and how? 
 
Now I’d like to ask some questions about the decision making process. 
2a) In general, how would you say decisions are made in your work place?  In your 
healthcare system? 
• Are decisions collaborative, bottom-up, top down, structured, non-structured? 
• Can you provide an example of how a decision in your practice setting is made, 
such as a decision about drug therapy [modify this example as needed based on 
the expertise of your interview subject]?  Who participates in making this decision?  
What sources of information do they use?  Is the decision by consensus or 
majority? How is the decision communicated to others? 
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2b) Can you describe the key characteristics of decision-making? 
 
 Interview instructions—select one of the follow scenarios below based on the maturity 
of your program.  Option 1.1 is for existing programmes and option 1.2 is for non-
existing programmes. 
 
1.1 Now I’d like to talk to you about your polypharmacy management programme.  Can you 
give me an overview of the programme, and why and how it got to where it is now? 
• How is the problem of polypharmacy articulated by your organisation or government, 
and 
• Why does the government or organisation see the need to address it now? 
• Would you say that there was a clearly articulated vision? 
 
1.2 Now I’d like to talk to you about medicines management in your country or institution.  
Can you give me an overview of how drug therapy is managed? 
• Has the problem of polypharmacy been articulated by your institution?  If not, why do 
you think this is? 
• Has there been any attempt to describe the benefits of polypharmacy and adherence 
management?  An example of this might be an economic evaluation of the impact of 
non-adherence or inappropriate polypharmacy. 
• How does a polypharmacy management or adherence plan fit within the goals of your 
institution, or, how does it not fit? 
• Have there been any attempts to draft any proposals around polypharmacy 
management and adherence?  How have these been received? 
 
 
One of our goals in this project is to understand how different polypharmacy programmes 
were conceived, developed, and implemented, and if no programme exists, why this is.  Now 
I’d like to get into some more specifics of your situation.   
 
 
 Interview instructions—select one of the follow scenarios below based on the maturity 
of your program.  Option 2.1 is for existing programmes and option 2.2 is for non-
existing programmes. 
 
2.1 I’d like to ask some questions about the initial planning phase. 
 
• Can you please describe the key characteristics of the planning phase? 
• How is planning addressed in your organisation and who is responsible? 
• Looking back to the start of the programme, how were the benefits assessed prior to 
implementation? 
• What economic evaluation, if any, was used in the planning and why?  
• Was a business case made for the adoption of the programme? If so please describe 
why. 
 
 
2.2 I’d like you to think about implementing a new polypharmacy programme.   
• Can you please describe some of the key steps that would be necessary for the initial 
planning phase? For example, the need to develop standardized practice guidelines, or 
create a working group on the issue. 
• In your organization, who would be responsible for this type of initiative?   
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• What elements of feasibility (bottlenecks/ enablers) would be used to determine if this 
type of programme would go forward? 
• Would an economic evaluation typically be part of the planning process? 
• Does a polypharmacy management programme make sense in the context of the 
ongoing work at your institution?  Does it fit with your goals and objectives?  Why or 
why not? 
 
[CONTEXT FOR INTERVIEWER—USE AS PROMPT IF NEEDED IN EITHER SCENARIO] 
For example, in Scotland, initially individual business cases would have been prepared that 
would explain the benefits to individual regional board.  When the first national guidance 
was produced evidence from the boards with economic benefits was gathered to help the 
boards build the case for undertaking the work.  For further information see Scottish 
polypharmacy guidance version 1.  
 
 
 Interview instructions—the following section refers to the implementation and 
integration of a programme into an organization.  Two sets of questions are provided 
under each heading, one for existing programmes and one for potential future 
programmes.  Only use one set during the interview depending on the status of your 
programme 
 
Now I’d like to learn some more about how the programme was introduced into the 
organization [OR how a future programme would be introduced to your organization]. 
 
Existing Programmes 
• How was the programme described to the clinicians who would be responsible for 
implementing it?  
• How were the benefits described? 
• How did it relate to your organizational goals? 
• Was there resistance to change?  From individuals or from larger groups, such as from 
a specific group of healthcare providers or policymakers.  
 
Future Programmes 
• Who would be responsible for describing the programme to clinicians responsible for 
implementing it? 
• Which target population would you address for the implementation of the program? 
Perhaps a chronic condition like diabetes or an age group such as frail elderly? 
• Do you anticipate that there would be resistance?  If so, from which groups?  
• Who are the major stakeholders, or, who are the people whose lives would be most 
affected by the implementation of a polypharmacy management programme?   
o Would these people be facilitators or detractors from the programme? 
o How would you work with the detractors? 
o How would the programme benefit from facilitators? 
 
 
The next group of questions involve the implementation of the programme. 
 
Existing Programmes 
• How would you say that the programme was initially received by those implementing 
it?   
o Was there buy in or were people sceptical of the benefits? 
• Were there any key individuals or champions involved in the implementation? 
 
 
12 
• What type of coalitions, management groups, or teams were formed to help 
implement the programme?  Who would you say had the primary leadership role? 
• Have the polypharmacy reviews enabled more multidisciplinary interactions with the 
pharmacists? 
• Are the patients supported to make decisions from the review? 
• Has support for the intervention changed over time? 
 
Future Programmes 
• How do you think this type of programme would be received by those responsible for 
implementing it? 
• Who would be the champions necessary for its success? 
• How would you set up a pilot to test and implement the model? 
• What type of coalitions, management groups or teams do you think would help with 
the implementation?  Who do you think should coordinate such an initiative? 
• What role do you see for patients in the implementation? 
 
Now I want to learn a little more about how you integrated the programme into the existing 
work load of your clinicians [OR how you would integrate a programme into the existing 
work load of your clinicians]. 
 
Existing Programmes 
• What type of training was provided? 
• If training was provided who was this for and why? 
• How did the programme fit with existing tasks? 
• Were new staffing patterns required?  Restructure departments?  Modify workflow? 
• Were additional resources required? 
• Was there an initial trial run or pilot programme prior to full-scale implementation? 
• How many units were involved in the initial implementation?  One unit geriatric ward 
in a hospital?  The whole institution?  More than one institution?  Has it been 
expanded to include more units? 
• What elements of the healthcare system were barriers to change? 
• What elements helped? 
 
Future Programmes 
• What type of training do you think would be necessary for the aforementioned target 
populations this type of initiative to succeed?  If so, for whom? 
• How do you see this new programme fitting in with existing tasks, such as 
training/literacy/programs/activities? 
• Do you think that a new staffing pattern would be required?  What other changes to 
personnel management do you think would be required? 
• Would this require additional resources? 
• What do you think would be the most successful strategy for implementing a new 
programme regarding the location and size of the programme?  For example, would 
you suggest a trial run in a hospital ward first? In the context of a stepwise approach? 
• What elements of your healthcare system do you think would be potential barriers or 
facilitators to implementing this type of programme? 
 
Finally I want to talk to you about the evaluation of your programme [OR of a future 
programme].   
 
Existing Programmes 
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Can you summarise the results of your programme? 
 
• What type of short term monitoring of outcomes was done?  How were these results 
shared with staff? 
• Why was monitoring undertaken? 
• How are the effects of the programme evaluated?   
• Were there any unintended outcomes, either positive or negative?  These might 
include things like additional paperwork, improved relationships between providers, or 
negative clinical outcomes from aggressive deprescribing. 
• Is staff motivation an issue that needs support?  Why or why not?  How has staff 
motivation been sustained? 
 
Future Programmes 
• How would you define and monitor the short term outcomes of such a programme?  
Are there mechanisms in place to share this type of information with your staff? 
• How else would you define and evaluate the success of this type of programme? 
• Do you think that staff motivation over the long term will be an issue that needs 
support? 
 
I’d like to understand a little more about the practice environment, especially around who 
makes drug therapy decisions.  
 
• Which health care providers have prescribing authority in your programme?     
• How healthcare decisions are typically made?  For example, by a multidisciplinary 
team or individual practitioners? 
• How are prescribing decisions made and why? 
• Would you describe the environment within your programme as collaborative?   
Hierarchical? Or in other terms (please explain)?  How has that shaped this 
programme?   
• Outside of physicians, do other health care providers such as nurses or pharmacists 
have increased clinical involvement in patient care such as prescribing authority, 
responsibility for patient education, or the development of drug therapy plans?  
 
Now I want to talk a little about your plans for the future.  
• Looking forward over the next 2-3 years, what are the goals and objectives for the 
programme [OR for your institution regarding medicines management]?  Please 
describe why these have been chosen. 
• What will be required to achieve these goals? 
 
  Interview instructions—the following group of questions only applies to countries with existing programmes. 
 
Finally, if you were advising someone on the development of a polypharmacy programme, 
what key piece of advice would you give them?  Is there anything you would have done 
differently in your programme, or anything that you see as essential to the success of a 
polypharmacy management programme?   
 
Thank you so much for your participation.  Before we end, is there anything that I did not ask 
you about that you would like to explain about the development and implementation of your 
polypharmacy programme [OR about the potential development of a polypharmacy and 
adherence programme]?   
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We may want to consult with you in the process of writing up the case studies to seek 
clarification on specific points – we hope you will be amenable to this? 
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Focus group discussion guide 
Hello, my name is [Moderator’s name] and this is my colleague [Note taker’s name].  Welcome 
to the discussion.  Today I would like to discuss your opinions of the SIMPATHY report 
regarding the management of polypharmacy and adherence. Everything you say is important 
to us and will help us determine if our findings reflect the true situation that patients and 
health care providers experience.  Please feel free to speak openly and use any language or 
words. There are no right or wrong answers.  Your name will not be written anywhere, which 
means that no one will know it was you who said something. You can choose to stop 
participating in this discussion at any time and you can choose not to respond to any question 
you don’t want to answer, but we hope you will feel free to contribute. 
 
Since this discussion is very important to us, we would like to audio record it, with your 
permission (confirm their consent).  My colleague [Note taker] will also be taking notes to 
make sure that we do not miss any important things that we will discuss today.   The recording 
and notes will be kept private and safe.  The discussion will take about 90 minutes.  Do you 
have any questions at this point?   We are now turning on the audio recorder. 
 
Brief Introduction and Context Setting: 
I’d like to briefly summarize some of the main points from the report. THIS WILL NEED TO BE 
DEVELOPED BY EACH PARTNER BASED ON THE RESULTS OF THEIR PARTICULAR REPORT. 
 
Initial Reaction: 
1. Ask each participant to write down three words or phrases that describe their initial 
reaction to the repot contents.  [Alternatively, or additionally at some point, ask each 
participant to write down the two strongest points of the report and the two points that 
need improvement or clarification].  Have participants share what they wrote down. 
 
Individual Experience: 
2. How would you say the description of polypharmacy management compares to your 
experience? 
a. What about the report fits with your experience? 
b. Are there aspects of the report that don’t fit with your experience? 
 
Questions 3-4 are for patients or care givers only 
3. Were you aware that there is an initiative in XX focusing on polypharmacy, or people 
taking many medications 
4. Has a doctor or other health care provider such as a nurse or pharmacist ever talked to you 
about your medicines plan?   
a. If so, what did they talk to you about? 
b. How did your experience compare to the one described in the report? 
 
Question five applies to policy makers and managers 
Now I’d like to ask your opinion about some of the specifics in the report. 
 
5. How does the description of the development and implementation of the [NAME OF 
PROGRAMME] polypharmacy programme match with your experience? 
a. The description of the evaluation? 
b. Management techniques described? 
 
General Feedback: 
6. Is there anything in the report that you feel is not accurate? 
7. What is the strongest aspect of the report? 
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8. Is there anything that you feel we have missed or that should be added to the report? 
 
Summarize key points prior to closing session: 
Before we finish I’d like to summarize what I heard as your main points regarding this report. 
 
Conclusion:  
Thank you for your time. If you have any additional questions or comments, you may contact 
[NAME], Study Coordinator, at PHONE or EMAIL.  
